Skip to main content

Table 3 Part 2. Clinical outcomes of the controlled study

From: Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial

Variables

Tranexamic acid (n = 24)

Placebo (n = 26)

P value

D-dimer at 0 hours, ng/mLa

448 (270–625)

1,069 (951–1,189)

<0.01

D-dimer at 4 hours, ng/mL

499 (364–633)

974 (880–1,069)

<0.01

D-dimer at 24 hours, ng/mL

433 (280–608)

976 (868–1,064)

<0.01

Plasminogen activator inhibitor 1 at 4 hours, ng/mL

88 (35–140)

129 (70–188)

0.04

Creatine-kinase at 0 hours, U/L

261 (199–322)

327 (270–383)

0.03

Creatine-kinase MB at 0 hours, U/L

41 (35–47)

63 (50–77)

<0.01

STNFR-1 at 4 hours, ng/mL

1,274 (958–1,590)

1,656 (1,175–2,138)

0.09

Interleukin-6 at 4 hours, pg/mL

236 (140–332)

362 (250–474)

0.12

Interleukin-6 at 24 hours, pg/mL

87 (61–114)

119 (88–151)

0.07

Twenty-four-hour bleeding, mL

464 (308–620)

1,037 (771–1,303)

<0.01

Total bleeding, mL

835 (407–1,263)

1,466 (1,116–1,818)

<0.01

RBCb units transfused within the first 4 hours (percentage)c

1 (4)

2 (7)

0.39

RBCb units until chest tube withdrawal (percentage)c

9 (38)

19 (73)

0.01

Plasma units until chest tube withdrawal (percentage)c

1 (4)

8 (31)

0.02

Inflammatory response after CPB, number (percentage)

4 (17)

11 (42)

0.047

Vasoplegic shock, number (percentage)

0

7 (27)

<0.01

Norepinephrine, hours

1.2 (0.5–2.4)

25.4 (5.6–45)

0.02

Mechanical ventilation, hoursd

6.5 (5–13.5)

12 (7–24)

0.02

Intensive care unit stay, daysd

3 (2–5.5)

3.5 (2–5)

0.96

Postsurgical hospital stay, daysd

4.5 (3–6)

4 (2–5)

0.34

  1. Values are expressed as mean and 95% confidence interval or as frequency and percentage. a0 hours represents intensive care unit admission after cardiopulmonary bypass (CPB); btotal red blood cell (RBC) and plasma until chest tube withdrawal; cpercentage of transfused patients; dvalues are expressed as median and interquartile range. STNFR-1, soluble tumor necrosis factor receptor type 1.